Spirea raises £2.4M to develop antibody drug conjugates in cancer
Funding of £2.4 million ($2.9 million) has been secured by UK-based company, Spirea Limited, to…
June 16, 2022 - 3 minutes
Antibody-drug conjugates
Check out the latest antibody-drug conjugate news. This section covers the latest updates on approvals, regulations, deals, and antibody–drug conjugate (ADC) technology.
Tubulis Rides Investment Wave in ADCs with €60M Series B
The German firm Tubulis has raised a €60M Series B round to advance cancer drugs…
May 3, 2022 - 3 minutes
ADC Approval Buoys Spirits in Cancer Treatment Space
The FDA recently approved an antibody-drug conjugate drug from ADC Therapeutics as a treatment for…
May 11, 2021 - 7 minutes
Update: Chinese Pharma Enlists Synaffix’s ADC Technology for Second Drug
Update (07/01/2020): Shanghai Miracogen has expanded its pre-existing license agreement with the Dutch biotech Synaffix.…
January 7, 2020 - 2 minutes
Update: Swiss Biotech’s Series E Expanded to €271M to Commercialize Antibody-Guided Cancer Chemotherapy
Update (09/07/2019): The Switzerland-based ADC Therapeutics has completed the final closing of a €271M ($303M)…
July 9, 2019 - 3 minutes
Mastering the Competitive World of Immuno-oncology
In recent years the oncology world has focused on using the immune system to target…
October 25, 2018 - 5 minutes
Update: Yet Another ADC Company Makes Bank, This Time in Series B
Update (29.06.2018): NBE Therapeutics has extended its Series B fundraising round by 20M CHF (€17.3M),…
June 29, 2018 - 3 minutes
New Antibody-Drug Conjugate Offers Hope to Hard-to-Treat Cancer Patients
ADC Therapeutics has tested its antibody-drug conjugate technology in drug-resistant cancers, yielding encouraging results. Swiss biotech…
December 11, 2017 - 3 minutes
German Biotech Reels in €34M for its Cancer-Killing Technology
Heidelberg Pharma is developing Antibody Targeted Amanitin Conjugates (ATACs), which combine antibody-drug conjugate technology with the…
November 21, 2017 - 1 minute
4th-Generation ADCs: Meet the Swiss Startup Perfecting the Technology
ADC development has progressed to the fourth generation. Serial entrepreneur Ulf Grawunder told me what…
October 4, 2017 - 5 minutes
New UK Team will develop Next-Generation Antibody-Drug Conjugates for Cancer
Glythera and IONTAS have partnered to develop next-generation antibody-drug conjugates that are less toxic and more potent against difficult-to-treat…
September 20, 2017 - 1 minute
Understand your Biologics: De-Risking the Biotech Pipeline
Characterizing biologics has become an essential step for successful drug development. We connected with SCIEX…
June 14, 2017 - 5 minutes
